HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.

AuthorsGouji Toyokawa, Mitsuhiro Takenoyama, Sawori Watanabe, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Yoshimasa Shiraishi, Yosuke Morodomi, Tomoyoshi Takenaka, Fumihiko Hirai, Masafumi Yamaguchi, Kenichi Taguchi, Takashi Seto, Yukito Ichinose
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 8 Issue 11 Pg. e96-8 (Nov 2013) ISSN: 1556-1380 [Electronic] United States
PMID24128725 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
Topics
  • Adenocarcinoma (drug therapy, genetics, pathology)
  • Adult
  • Anaplastic Lymphoma Kinase
  • Crizotinib
  • Disseminated Intravascular Coagulation (drug therapy, genetics, pathology)
  • Female
  • Gene Rearrangement
  • Humans
  • In Situ Hybridization, Fluorescence
  • Liver Neoplasms (drug therapy, genetics, secondary)
  • Lung Neoplasms (drug therapy, genetics, pathology)
  • Protein Kinase Inhibitors (therapeutic use)
  • Pyrazoles (therapeutic use)
  • Pyridines (therapeutic use)
  • Receptor Protein-Tyrosine Kinases (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: